
Contents

Preface	xxv
Abhishek KUMAR, Priya BATTA and J.P. ANANTH	

Introduction	xxvii
Abhishek KUMAR, Priya BATTA and J.P. ANANTH	

Chapter 1. ML-driven Early Detection of Retinal Diseases in Primary Care Settings	1
V.H. KARAMBELKAR and Patil Ashish N.	
1.1. Introduction.	1
1.2. Burden of retinal diseases and importance of early detection	3
1.2.1. Epidemiological burden	3
1.2.2. Socioeconomic consequences	3
1.2.3. Importance of early detection.	4
1.2.4. Challenges in conventional screening	4
1.2.5. Rationale for primary care integration.	4
1.2.6. Machine learning contribution toward the burden.	5
1.3. ML approaches for retinal disease detection	5
1.3.1. Conventional ML approaches.	5
1.3.2. Constructionism and convolutional neural networks	6
1.3.3. Transfer learning and pre-trained models.	6
1.3.4. Multimodal learning and ensemble learning	7
1.3.5. Benefit of ML-based practices in primary care	7
1.3.6. Weaknesses of existing methods	7

1.4. Applications in primary care settings.	8
1.4.1. Fundus photography in primary care	8
1.4.2. ML-supported teleophthalmology	9
1.4.3. General practitioner decision-support systems.	9
1.4.4. Real-world implementations	10
1.4.5. Advantages to healthcare systems	10
1.4.6. Obstacles to primary care adoption	10
1.4.7. Future prospects.	11
1.5. Validation and clinical implementation studies.	11
1.5.1. ML model clinical validation	11
1.5.2. Primary care implementation in practice	12
1.5.3. Regulatory approvals and guidelines	12
1.5.4. Shortcoming of validation studies	12
1.5.5. Implications on primary care practice	13
1.6. Challenges and limitations	13
1.6.1. Data representativeness and data quality	13
1.6.2. Generalizability across devices and clinical settings	13
1.6.3. Interpretability and clinician trust	14
1.6.4. Integration with clinical working processes	14
1.6.5. Regulatory and ethical challenges	14
1.6.6. Barriers of costs and accessibility	15
1.6.7. Patient acceptance and ethical concerns.	15
1.7. Future directions and emerging trends	15
1.7.1. Accountable and understandable AI	15
1.7.2. Federated learning and privacy-preserving learning	16
1.7.3. Multimodal and holistic diagnostics	16
1.8. Conclusion	16
1.9. References	17

Chapter 2. Explainable AI in Ophthalmology: Building Trust in Automated Diagnosis 21

B.S. JOSHI and Jujar Komal M.

2.1. Introduction.	21
2.2. Foundations of explainable AI	23
2.2.1. Understanding the black-box nature of AI models	23
2.2.2. Interpretability versus explainability	24
2.2.3. XAI approaches relevant to ophthalmology	24
2.2.4. Importance of XAI for trust and clinical adoption.	25
2.3. Applications of XAI in ophthalmology	26
2.3.1. Diabetic retinopathy	26
2.3.2. Age-related macular degeneration (AMD)	27

2.3.3. Glaucoma detection	27
2.3.4. Retinopathy of prematurity (ROP).	27
2.3.5. Other applications	28
2.4. Challenges in implementing explainable AI in ophthalmology	28
2.4.1. Technical challenges	29
2.4.2. Clinical integration barriers	29
2.4.3. Regulatory and ethical concerns	29
2.4.4. Computational and resource constraints	30
2.4.5. Trust and user acceptance	30
2.5. Future directions and opportunities.	30
2.5.1. Standardization of XAI methods	30
2.5.2. Integration with multi-modal imaging and genomics	31
2.5.3. Human–AI collaboration frameworks	31
2.5.4. Ethical AI and bias mitigation	32
2.5.5. Real-world deployment and continuous learning	32
2.5.6. Interdisciplinary collaborations.	33
2.5.7. Future role in teleophthalmology and remote monitoring	33
2.5.8. Clinical support integration with large language models (LLMs)	33
2.5.9. Training and education for clinicians using XAI	34
2.6. Conclusion	34
2.7. References	35

Chapter 3. Federated Learning Approaches for Privacy-Preserving Ophthalmic AI Models

Girish Arun GADRE and Pawar Atul NAMDEV

3.1. Introduction.	39
3.2. Fundamentals of FL in healthcare.	41
3.2.1. Origins and relevance to healthcare	41
3.2.2. FL workflow and core algorithm.	42
3.2.3. Architectures of federated learning	42
3.2.4. Privacy-preserving mechanisms in FL	43
3.2.5. Healthcare-specific challenges for FL.	43
3.3. Applications of FL in ophthalmology	44
3.3.1. DR screening	44
3.3.2. Glaucoma detection and progression monitoring	44
3.3.3. Age-related macular degeneration (AMD) and retinal vascular diseases	45
3.3.4. Pediatric ophthalmology and rare diseases	45
3.3.5. Personalized ophthalmic AI models	46
3.3.6. Integration with multimodal ophthalmic data	46

3.4. Technical challenges in ophthalmic FL	46
3.4.1. Data heterogeneity across institutions	47
3.4.2. Class imbalance and rare diseases	47
3.4.3. Communication efficiency and bandwidth limitations	48
3.4.4. System and model heterogeneity	48
3.4.5. Privacy leakage risks in FL	48
3.4.6. Regulatory and interoperability barriers	49
3.5. Privacy and security enhancements in ophthalmic FL	50
3.5.1. Differential privacy (DP)	50
3.5.2. Homomorphic encryption	51
3.5.3. Secure multi-party computation (SMPC)	51
3.5.4. Hybrid privacy-preserving strategies	51
3.6. The future of FL in ophthalmology and clinical applications	52
3.6.1. Technical advancements for scalable ophthalmic FL	52
3.6.2. Personalization in federated ophthalmic models	53
3.6.3. Regulatory and ethical considerations	53
3.6.4. Clinical workflow integration	53
3.7. Conclusion	54
3.8. References	54

Chapter 4. AI-Powered Screening for Diabetic Retinopathy in Underserved Populations 57

Anjali PATIL and Kadam Shrikant RANGRAO

4.1. Introduction	57
4.2. Overview of AI in medical imaging	59
4.3. AI-powered DR screening technologies	60
4.3.1. Fundus photography-based AI systems	61
4.3.2. AI-based optical coherence tomography (OCT)	61
4.3.3. Smartphone-based fundus imaging and AI	61
4.3.4. Edge AI and offline deployments	62
4.3.5. Comparative evaluation of modalities	62
4.3.6. Integration with teleophthalmology	63
4.3.7. Implementation considerations	64
4.4. Applications in underserved populations	64
4.4.1. Teleophthalmology and AI integration	64
4.4.2. Community-based screening programs	64
4.4.3. Mobile health (mHealth) initiatives	65
4.4.4. Role of non-specialist health workers	65
4.4.5. Regional case studies	65
4.5. Challenges and limitations	66
4.5.1. Data quality and representation	66

4.5.2. Algorithmic bias and generalizability	66
4.5.3. Regulatory and ethical concerns	66
4.5.4. Cost-effectiveness and sustainability	67
4.5.5. Workforce and training barriers	67
4.5.6. Social and cultural acceptance	67
4.6. Future directions	68
4.6.1. Federated learning and global collaboration	68
4.6.2. Multimodal and predictive models	68
4.6.3. Personalized and adaptive screening	68
4.6.4. Integration with primary care and community health	69
4.6.5. Policy and regulatory frameworks	69
4.7. Conclusion	69
4.8. References	70

Chapter 5. Deep Learning for Multimodal Integration in Retinal Disease Classification.

Gaurav PARANJPE and Inamdar Sharifnawaj Y.

5.1. Introduction	73
5.2. Retinal diseases: clinical and imaging perspectives	74
5.2.1. Diabetic retinopathy	75
5.2.2. Age-related macular degeneration	75
5.2.3. Glaucoma	75
5.2.4. Retinal vein occlusion	76
5.2.5. Clinical imaging processes	76
5.3. Imaging modalities in retinal disease classification	76
5.3.1. Fundus photography	76
5.3.2. OCT	77
5.3.3. OCT angiography (OCTA)	77
5.3.4. Fluorescein angiography (FA)	77
5.3.5. Patient metadata and electronic health records (EHR)	77
5.3.6. Complementary strengths	78
5.4. Deep learning in ophthalmology	78
5.4.1. Convolutional neural networks	78
5.4.2. Transformer-based architectures	78
5.4.3. Transfer learning and pretrained models	79
5.4.4. Domain-specific model adaptations	79
5.4.5. Benchmarks and single-modality successes	79
5.4.6. Limitations of single-modality approaches	80
5.5. Multimodal integration strategies	80
5.5.1. Early fusion	80
5.5.2. Intermediate fusion	81

5.5.3. Late fusion	81
5.5.4. Attention mechanisms in multimodal fusion	82
5.5.5. Graph-based and hybrid fusion models	82
5.5.6. Comparative evaluation of fusion methods	82
5.5.7. Case studies in multimodal retinal disease classification	84
5.6. Challenges and limitations	84
5.6.1. Limited availability multimodal datasets	84
5.6.2. Imaging devices and imaging protocol heterogeneity	84
5.6.3. Interpretability and clinical trust	85
5.6.4. Computational and infrastructure challenges in multimodal deep learning	85
5.6.5. Regulatory and ethical considerations	85
5.7. Emerging trends and future directions	85
5.7.1. Self-supervised and contrastive learning	85
5.7.2. Data augmentation	86
5.7.3. Explainable AI (XAI)	86
5.7.4. Federated and privacy-preserving learning	86
5.8. Conclusion	86
5.9. References	87

Chapter 6. Optimizing Ophthalmic Surgery Outcomes Using Predictive ML Algorithms 91

D.B. SHIRKE and Patil Zunjar V.

6.1. Introduction	92
6.2. Overview of ML in ophthalmology	93
6.2.1. The principles of ML in ophthalmology	93
6.2.2. Data sources for predictive ML	94
6.2.3. Evolution of ML in ophthalmic surgery	95
6.2.4. Strengths of ML in ophthalmology	95
6.2.5. Current limitations	95
6.3. Applications of predictive ML in specific ophthalmic surgeries	96
6.3.1. Cataract surgery	96
6.3.2. Refractive surgery	96
6.3.3. Corneal transplantation	97
6.3.4. Glaucoma surgery	97
6.3.5. Vitreoretinal surgery	98
6.4. Methodological frameworks of predictive ML models	99
6.4.1. Data collection and preprocessing	99
6.4.2. Algorithm selection	99
6.4.3. Model training and validation	100
6.4.4. Interpretability and explainability	100

6.5. Imaging, EHR and cloud-based integration	100
6.5.1. Integrated with imaging systems	101
6.5.2. EHR integration.	101
6.5.3. Cloud-based platforms	102
6.5.4. Challenges in integration	102
6.6. Benefits in clinical practice	102
6.6.1. Improved accuracy and predictability	103
6.6.2. Enhanced personalization of care	103
6.6.3. Real-time decision support	103
6.6.4. Patient engagement and satisfaction	103
6.6.5. Efficiency and resource optimization	104
6.7. Challenges and limitations	104
6.7.1. Data quality and representativeness	104
6.7.2. Generalizability and validation	104
6.7.3. Interpretability and clinical trust	105
6.7.4. The integration with surgical workflow	105
6.8. Future directions	105
6.8.1. Multi-modal data fusion	105
6.8.2. Real-time intraoperative AI	106
6.8.3. Federated and collaborative learning	106
6.8.4. One with robotics and augmented reality	106
6.8.5. Adaptive and continually learning systems	106
6.9. Conclusion	107
6.10. References.	107

Chapter 7. The Role of Reinforcement Learning in Adaptive Vision Therapy 111

Sanvedya KADAM and Shinde Patil Girisha SURESH

7.1. Introduction.	111
7.2. Overview of adaptive vision therapy	113
7.3. Fundamentals of RL for healthcare applications	114
7.4. RL in adaptive vision therapy: applications and case studies.	116
7.4.1. Adaptive exercise adjustment using RL.	117
7.4.2. Virtual reality and gamified environments	117
7.4.3. Multi-modal feedback integration	118
7.4.4. Personalized therapy scheduling	118
7.4.5. Clinical evidence and case studies	118
7.4.6. System architectures and implementation considerations	118
7.4.7. Future implications	120
7.5. Challenges and future directions	120
7.5.1. Data limitations and sample size	120

7.5.2. Safety and clinical oversight	121
7.5.3. Interpretability and trust	121
7.5.4. Integration with clinical workflows	121
7.5.5. Ethical considerations	122
7.5.6. Future directions	122
7.6. Conclusion	122
7.7. References	123

Chapter 8. Augmenting Human Expertise: AI Decision Support Systems in Ophthalmology Clinics. 127

Prajakta PATIL and Natu Milind A.

8.1. Introduction.	128
8.2. Evolution of AI decision support in ophthalmology	129
8.3. Core AI technologies in ophthalmology decision support systems . . .	130
8.3.1. Machine learning	130
8.3.2. Deep learning	131
8.3.3. Natural language processing	131
8.3.4. Multimodal integration	132
8.4. Clinical applications of AI decision support systems in ophthalmology	132
8.4.1. Diabetic retinopathy	132
8.4.2. Glaucoma	132
8.4.3. Age-related macular degeneration	133
8.4.4. Corneal and anterior segment disorders.	133
8.5. AI DSS implementation in ophthalmology clinics	133
8.5.1. Being able to interoperate with EHRs.	134
8.5.2. Workflow optimization in clinical practice.	134
8.5.3. Training and clinician acceptance	134
8.5.4. Infrastructure and scalability	135
8.5.5. Patient engagement and perceptions.	135
8.6. Ethical, legal and privacy concerns in AI DSS for ophthalmology	135
8.6.1. Ethical challenges: fairness, bias and accountability	136
8.6.2. Legal and regulatory considerations	136
8.6.3. Data privacy and security	137
8.6.4. Patient autonomy and informed consent	137
8.7. Challenges and limitations of AI DSS in ophthalmology	138
8.7.1. Technical limitations	138
8.7.2. Data-related challenges	138
8.7.3. Clinical adoption barriers	138
8.7.4. Infrastructure and cost constraints	139

8.8. Future prospects of AI DSS in ophthalmology	140
8.8.1. Toward personalized ophthalmology	140
8.8.2. Multimodal and cross-domain integration	140
8.8.3. Federated and collaborative learning	141
8.8.4. Enhancing explainability and clinician trust	141
8.8.5. Global accessibility and tele-ophthalmology.	141
8.9. Conclusion	142
8.10. References.	142

Chapter 9. Transfer Learning Applications for Rare Ocular Disease Detection. 145

Sonali PATIL and Shinde Rutuja P.

9.1. Introduction.	145
9.2. Fundamentals of transfer learning in medical imaging	147
9.2.1. Types of transfer learning	147
9.2.2. Why transfer learning is crucial for rare ocular diseases	148
9.2.3. Architectures commonly used in transfer learning	148
9.2.4. Modalities supporting transfer learning in ophthalmology.	148
9.2.5. Limitations of transfer learning in medical imaging	149
9.2.6. The role of emerging paradigms	149
9.3. Transfer learning applications in rare ocular disease detection	149
9.3.1. Transfer learning in fundus imaging.	149
9.3.2. Transfer learning in OCT	150
9.3.3. Multimodal imaging approaches	151
9.3.4. Case-specific applications in rare ocular diseases	151
9.3.5. Emerging innovations	152
9.4. Challenges and limitations	153
9.4.1. Data scarcity and imbalance	153
9.4.2. Domain shift across imaging devices and populations	153
9.4.3. Interpretability and clinical trust	154
9.4.4. Computational and resource constraints	154
9.4.5. Ethical and regulatory challenges	154
9.4.6. Clinical workflow integration.	155
9.5. Future directions and clinical translation	155
9.5.1. Self-supervised and unsupervised learning.	155
9.5.2. Few-shot and meta-learning approaches	156
9.5.3. Multimodal and multitask learning	156
9.5.4. Explainable and trustworthy AI	157
9.5.5. Clinical translation and deployment	157
9.5.6. Toward precision ophthalmology	157

9.6. Conclusion	158
9.7. References	158

Chapter 10. Real-Time AI Assistance in Slit-Lamp

Examination and Diagnosis	163
--	------------

Renuka SARWATE and Deshmukh Manoj JANARDHAN

10.1. Introduction	163
10.2. Technological foundations of real-time AI in slit-lamp examination	166
10.2.1. Computer vision and deep learning approaches	166
10.2.2. Real-time processing and edge computing	166
10.2.3. The hardware can integrate with slit-lamp hardware	167
10.2.4. Data pipelines and standardization	167
10.2.5. Workflow integration and clinical usability.	167
10.3. Clinical applications of real-time AI in slit-lamp examination	168
10.3.1. Cataract detection and grading	168
10.3.2. Corneal pathologies.	169
10.3.3. Conjunctival lesions and ocular surface disease	169
10.3.4. Glaucoma assessment	169
10.3.5. Uveitis and inflammatory disorders	170
10.3.6. Trauma and emergency applications.	170
10.3.7. Pediatric and geriatric applications.	170
10.3.8. Interconnection with teleophthalmology	171
10.4. Ethical complications and challenges in real-system AI-assisted slit-lamp examination	172
10.4.1. Variability and quality of slit-lamp data.	172
10.4.2. Explainability and clinician trust	173
10.4.3. Workflow integration and usability	173
10.4.4. Ethical and equity considerations.	173
10.4.5. Regulatory and legal barriers	174
10.5. Future prospects and opportunities of real-time AI-assisted slit-lamp examination	174
10.5.1. Advances in edge computing and on-device AI	174
10.5.2. The multimodal ophthalmic imaging	175
10.5.3. Personalized and adaptive AI models	175
10.5.4. Explainability and human–AI collaboration	175
10.5.5. Expanding access through teleophthalmology	176
10.5.6. Regulatory evolution and collaborative frameworks	176
10.5.7. Ethical and equitable deployment	177
10.6. Conclusion	177
10.7. References.	178

Chapter 11. Unsupervised Learning Techniques for Discovery of Novel Retinal Biomarkers 181

V.H. KARAMBELKAR and Sonake Vanita V.

11.1. Introduction	181
11.2. Unsupervised learning methodologies for retinal imaging	183
11.2.1. Clustering approaches	184
11.2.2. Dimensionality reduction techniques	184
11.2.3. Deep representation learning	185
11.2.4. Self-supervised learning paradigms	186
11.2.5. Hybrid and multimodal approaches	186
11.3. Applications of unsupervised learning in retinal biomarker discovery	186
11.3.1. Diabetic retinopathy	187
11.3.2. Age-related macular degeneration	187
11.3.3. Glaucoma	188
11.3.4. Neurodegenerative disorders	189
11.3.5. Cardiovascular and systemic diseases	189
11.3.6. Rare and emerging applications.	190
11.4. Challenges and limitations	190
11.4.1. Data quality and variability	190
11.4.2. Lack of ground truth for validation.	191
11.4.3. Interpretability of learned features	191
11.4.4. Generalizability across populations	191
11.4.5. Integration with multimodal and non-imaging data	192
11.4.6. Limited clinical translation	192
11.5. Future directions	192
11.5.1. Explainable and interpretable unsupervised learning	193
11.5.2. Multimodal and multi-omics integration	193
11.5.3. Longitudinal and predictive modeling	193
11.5.4. Clinical trials and biomarker qualification	194
11.5.5. Interaction with personalized and preventive medicine.	194
11.6. Conclusion	194
11.7. References.	195

Chapter 12. Developing Robust AI Models Against Bias in Ophthalmic Datasets 199

B.S. JOSHI and Naikawadi Swapnil SANJAY

12.1. Introduction	199
12.2. Sources of bias in ophthalmic datasets	201
12.2.1. Patient-level bias	201

12.2.2. Acquisition-level bias	202
12.2.3. Algorithmic and labeling bias	203
12.3. Approaches to bias detection and quantification	204
12.3.1. Fairness metrics for ophthalmic AI.	204
12.3.2. Statistical approaches.	205
12.3.3. Explainable AI for bias identification	205
12.3.4. External validation and benchmarking.	205
12.3.5. Composite bias auditing frameworks	206
12.4. Strategies for mitigating bias in ophthalmic AI models	206
12.4.1. Data-centric approaches	206
12.4.2. Model-centric approaches	208
12.4.3. Hybrid approaches	209
12.5. Clinical and ethical implications.	209
12.5.1. Clinical risks of biased AI	210
12.5.2. Impact on patient trust and clinician adoption	210
12.5.3. Ethical responsibility and equity	210
12.5.4. Regulatory and policy considerations	211
12.6. Future directions	211
12.6.1. Global collaborative dataset initiatives	211
12.6.2. Multimodal and longitudinal data integration	211
12.6.3. Explainable and trustworthy AI.	212
12.6.4. Adaptive and continuous learning systems	212
12.7. Conclusion	212
12.8. References.	213

Chapter 13. Self-Supervised Learning for Retinal Image

Feature Extraction in Low-Label Settings 217

Girish Arun GADRE and Patil Monika VIRENDRA

13.1. Introduction	218
13.2. Principles of SSL in medical imaging	219
13.2.1. Core concept of SSL	219
13.2.2. Pretext tasks in medical imaging	219
13.2.3. Reasons why the use of SSL is appropriate in retinal imaging	220
13.2.4. Comparison with traditional transfer learning (SSL)	220
13.2.5. Interaction with other paradigms of learning	220
13.2.6. Evaluation metrics and benchmarks	221
13.3. Retinal image feature extraction by methods of SSL.	221
13.3.1. Contrastive learning methods	221
13.3.2. Masked image modeling.	222
13.3.3. Generative pretraining	222

13.3.4. Hybrid SSL approaches	223
13.3.5. Data augmentation strategies	223
13.3.6. Computational considerations	223
13.3.7. Comparative performance	223
13.4. Applications of SSL in retinal image analysis	225
13.4.1. Disease classification	225
13.4.2. Retinal image segmentation	225
13.4.3. Anomaly detection and rare disease identification	226
13.4.4. Longitudinal progression modeling	226
13.4.5. Cross-domain generalization and transferability	226
13.4.6. Multi-modes integration with clinical data and multi-modes imaging	227
13.5. Challenges, limitations and future directions	227
13.5.1. Challenges	227
13.5.2. Future directions	229
13.6. Conclusion	230
13.7. References	231

Chapter 14. ML-Enhanced OCT Image Segmentation for Glaucoma Progression Monitoring 235

Anjali PATIL and Patil Milin D.

14.1. Introduction	235
14.2. OCT in glaucoma diagnosis and monitoring	237
14.2.1. OCT biomarkers for glaucoma diagnosis	237
14.2.2. OCT in progression monitoring	237
14.2.3. Limitations of conventional OCT analysis	238
14.2.4. Rationale for ML integration	238
14.3. Principles of ML for medical image segmentation	239
14.3.1. Fundamentals of ML in imaging	239
14.3.2. Deep learning and neural networks	239
14.3.3. Training requirements and data challenges	240
14.3.4. Evaluation metrics for segmentation performance	240
14.3.5. Benefits compared to the traditional methods	241
14.4. ML-enhanced OCT segmentation: techniques and architectures	241
14.4.1. CNNs for retinal segmentation	241
14.4.2. Recurrent neural networks (RNNs) and sequential modeling	241
14.4.3. Transformer architectures in OCT segmentation	242
14.4.4. Generative adversarial networks (GANs) to data augmentation and segmentation	242
14.4.5. Multi-task and ensemble learning approaches	243

14.4.6. Transfer learning and domain adaptation	243
14.4.7. Practical considerations in model deployment	243
14.5. Applications in glaucoma progression monitoring	245
14.5.1. Detecting subtle structural changes	245
14.5.2. ML model-based longitudinal monitoring	245
14.5.3. Structure–function integration	246
14.5.4. Personalized risk stratification	246
14.5.5. Clinical decision support and workflow integration	246
14.5.6. Research and clinical trials applications.	247
14.5.7. Limitations in current clinical applications	247
14.6. Challenges and limitations	247
14.6.1. Data limitations and generalizability.	248
14.6.2. Model interpretability and clinical trust	248
14.6.3. Integration into clinical workflows.	248
14.6.4. Regulatory and ethical challenges	248
14.6.5. Clinical validation gaps	249
14.7. Future directions	249
14.7.1. Multimodal data integration	249
14.7.2. Federated and privacy-preserving learning	249
14.7.3. Real-time and edge computing solutions	250
14.7.4. Explainable AI and clinical trust	250
14.7.5. Roadmap for translation	250
14.7.6. Roadmap for practical medical application	250
14.8. Conclusion	251
14.9. References.	251

Chapter 15. Predictive Modeling of Myopia Progression in Children Using AI 255

Gaurav PARANJPE and Petkar Rajendra VASANTRAO

15.1. Introduction	255
15.2. Epidemiology and burden of childhood myopia	257
15.2.1. Global prevalence trends.	257
15.2.2. Age of onset and progression	257
15.2.3. Social and economic implication: the socioeconomic and educational effect	257
15.2.4. Threat of long-term ocular complications.	258
15.2.5. Public health implications	258
15.3. Risk factors in myopia progression	258
15.3.1. Genetic factors.	258
15.3.2. Environmental and behavioral factors	259

15.3.3. Ocular biometric factors	259
15.3.4. Interplay of risk factors.	260
15.3.5. Implications for predictive modeling	260
15.4. Traditional prediction methods and limitations	261
15.4.1. Refractive error assessments	261
15.4.2. AL growth curves	261
15.4.3. Risk factor-based clinical models.	262
15.4.4. Screening and population-level approaches.	262
15.5. AI in ophthalmology.	262
15.5.1. Evolution of AI in ophthalmology	262
15.5.2. AI for predictive modeling.	262
15.5.3. Clinical impact.	263
15.5.4. Barriers and ongoing research.	263
15.6. AI techniques for predictive modeling of myopia	263
15.6.1. ML approaches	264
15.6.2. DL approaches.	264
15.6.3. Hybrid and multimodal models	265
15.6.4. Comparative insights	266
15.7. Applications of AI models in predicting myopia progression	266
15.7.1. Individualized risk prediction	266
15.7.2. Longitudinal progression models.	267
15.7.3. Population-level screening tools	267
15.8. Intervention with clinical decision-making and personalized care	267
15.8.1. Personalized risk stratification	268
15.8.2. Treatment optimization and monitoring.	268
15.8.3. EHRs established to support the execution of the EHR system	268
15.8.4. Enhancing patient and family engagement	268
15.9. Challenges and limitations of AI-based prediction	269
15.9.1. Data quality and availability.	269
15.9.2. Algorithm transparency and interpretability	269
15.9.3. Validation and generalizability	269
15.9.4. Incorporation into clinical processes.	269
15.9.5. Ethical and legal concerns	270
15.10. Future directions in AI-driven myopia prediction.	270
15.10.1. Development of large-scale multimodal data ecosystems.	270
15.10.2. Incorporation of genomics and personalized medicine	271
15.10.3. Advancements in DL and hybrid models	271
15.11. Conclusion.	271
15.12. References	272

Chapter 16. Combining Genomics and Imaging Data in Ophthalmology Using Multimodal AI	275
D.B. SHIRKE and Garagate Amruta K.	
16.1. Introduction to multimodal AI in ophthalmology.	276
16.2. Genomics in ophthalmology	277
16.2.1. Clinical and biological significance of genomics in ophthalmology.	277
16.2.2. Types of genomic data in ophthalmic research.	278
16.2.3. AI in genomic data interpretation.	279
16.2.4. Multi-omics integration	280
16.2.5. Challenges in genomic AI	280
16.3. Advances in ophthalmic imaging for AI applications	280
16.3.1. Ophthalmology as a cornerstone of imaging	280
16.3.2. Key imaging modalities	280
16.3.3. AI for feature extraction and pattern recognition	281
16.3.4. Imaging biomarkers for disease prediction	281
16.3.5. Advancements beyond traditional DL	282
16.3.6. Toward multimodal integration	282
16.4. Integration of genomics and imaging data using multimodal AI	282
16.4.1. Multimodal AI architectures.	283
16.4.2. Clinical applications	283
16.4.3. Interpretability and explainable AI (XAI).	284
16.4.4. Integration with electronic health records (EHR)	284
16.4.5. Technical challenges	284
16.5. Challenges, limitations and future directions	285
16.5.1. Data-related challenges.	285
16.5.2. Computational and model complexity	285
16.5.3. Clinical translation barriers	286
16.5.4. Ethical, privacy and societal considerations	286
16.5.5. Future research directions	287
16.6. Conclusion	288
16.7. References.	288
 Chapter 17. Benchmarking Ophthalmology AI Models: Challenges in Dataset Standardization	 293
Sanvedya KADAM and Bardol Shabana M.	
17.1. Introduction	293
17.2. The role of AI in ophthalmology	295
17.3. Current practices in dataset development	297
17.3.1. Image acquisition	297

17.3.2. Data curation and preprocessing	297
17.3.3. Annotation practices	297
17.3.4. Dataset size and diversity	298
17.3.5. Quality control.	298
17.3.6. Data sharing and accessibility.	298
17.3.7. Current benchmarks and dataset initiatives	299
17.4. Challenges in dataset standardization.	299
17.4.1. Variability in imaging modalities.	299
17.4.2. Differences in annotation and ground truth	299
17.4.3. Imbalanced and biased datasets	300
17.4.4. Lack of demographic diversity	300
17.4.5. QC inconsistencies	301
17.4.6. Data privacy and sharing barriers.	301
17.5. Benchmarking ophthalmology AI models	303
17.5.1. Existing benchmarks and evaluation metrics	303
17.5.2. Reproducibility issues	303
17.5.3. Model generalizability across datasets.	304
17.5.4. Benchmarking in multi-disease and longitudinal settings	304
17.5.5. The role of competitions and shared challenges	304
17.6. Recent initiatives toward standardization	305
17.6.1. Multi-institutional collaborations.	305
17.6.2. Federated learning and privacy-preserving frameworks	305
17.6.3. Open-source platforms and shared datasets.	305
17.6.4. Standardized annotation protocols	306
17.6.5. Regulatory and professional society initiatives.	306
17.7. Regulatory and ethical considerations	306
17.7.1. The role of regulatory agencies	306
17.7.2. Ethical dimensions of dataset standardization	307
17.7.3. Transparency and explainability	307
17.7.4. Global equity and access.	307
17.7.5. Moving toward ethical standardization	307
17.8. Conclusion	308
17.9. References.	308

Chapter 18. NLP for Clinical Note Analysis in Ophthalmic Practice	313
Prajakta PATIL and Kadam Shweta A.	

18.1. Introduction	313
18.2. Evolution of NLP in healthcare and relevance to ophthalmology	315
18.2.1. Early rule-based systems.	315
18.2.2. Transition to statistical and machine learning approaches	316

18.2.3. The deep learning revolution	316
18.2.4. Transformer models and clinical adaptations.	316
18.2.5. Relevance to ophthalmology	317
18.3. Challenges of clinical note analysis in ophthalmology.	317
18.3.1. Domain-specific language and abbreviations.	317
18.3.2. Narrative variability among clinicians.	318
18.3.3. Integration of multimodal data	318
18.3.4. Limited availability of annotated datasets.	318
18.3.5. Handling of context and negation	318
18.3.6. Interoperability and standardization	319
18.4. Applications of NLP in ophthalmology	320
18.4.1. Disease classification and risk prediction	320
18.4.2. Automated summarization and information extraction	321
18.4.3. Clinical decision support.	321
18.4.4. Population health and research applications	322
18.4.5. Patient engagement and personalized care	322
18.5. Emerging trends in ophthalmic NLP	323
18.5.1. LLMs and ophthalmology	323
18.5.2. Multimodal NLP systems	323
18.5.3. Explainable and trustworthy NLP	324
18.5.4. Federated and privacy-preserving learning	324
18.5.5. Clinical workflow connectivity	324
18.5.6. NLP for global ophthalmology and telemedicine	325
18.6. Ethical, privacy and practical considerations	325
18.6.1. Data privacy and security	325
18.6.2. Bias and fairness in NLP models	326
18.6.3. Accountability and clinical responsibility.	326
18.6.4. Practical barriers to implementation	326
18.7. Future directions	326
18.7.1. Toward ophthalmology-specific LLPs.	327
18.7.2. Real-time clinical decision support.	327
18.7.3. Multilingual and cross-cultural NLP	327
18.7.4. Synergy with imaging and genomic data	328
18.8. Conclusion	328
18.9. References.	329

Chapter 19. Using ML to Analyze Eye Movement Patterns in Neurological and Psychiatric Diagnosis 333

Sonali PATIL and Kale Amruta B.

19.1. Introduction	333
------------------------------	-----

19.2. The window of mental activity of the brain is the eye movement . . .	335
19.2.1. Neural basis of eye movements	335
19.2.2. Eye movement alterations in neurological disorders	336
19.2.3. Eye movement alterations in psychiatric disorders	336
19.2.4. Eye movements as biomarkers	336
19.2.5. Integration with ML	338
19.3. Eye-tracking technologies and data acquisition	338
19.3.1. Evolution of eye-tracking systems	338
19.3.2. Types of data collected	338
19.3.3. Preprocessing and feature extraction	339
19.3.4. Data collection protocols	339
19.3.5. Challenges in eye-tracking data acquisition	340
19.4. Machine learning for eye movement analysis	340
19.4.1. Overview of ML in eye movement research	340
19.4.2. Feature engineering for oculomotor data	340
19.4.3. Supervised learning approaches	341
19.4.4. Unsupervised learning and clustering	341
19.4.5. Deep learning and representation learning	342
19.4.6. Multimodal fusion approaches	342
19.5. Applications in neurological disorders	343
19.5.1. AD and dementia	343
19.5.2. Parkinson's disease	343
19.5.3. Stroke and multiple sclerosis	344
19.6. Applications in psychiatric disorders	344
19.6.1. Schizophrenia	344
19.6.2. Autism spectrum disorder	345
19.6.3. Attention-deficit/hyperactivity disorder	345
19.6.4. Mood disorders	345
19.7. Challenges and limitations	346
19.7.1. Data variability and standardization	346
19.7.2. Generalizability of ML models	346
19.7.3. Interpretability and clinical acceptance	346
19.7.4. Ethical and privacy concerns	347
19.8. Future directions	347
19.8.1. Multimodal integration	347
19.8.2. Advances in hardware and accessibility	347
19.8.3. Personalized and adaptive models	348
19.8.4. Explainable and trustworthy AI	348
19.9. Conclusion	348
19.10. References	349

Chapter 20. AI for Personalized Drug Response Prediction in Age-related Macular Degeneration	353
Renuka SARWATE and Patil Ashish N.	
20.1. Introduction	354
20.2. AI in ophthalmology: a brief overview	355
20.3. Pathophysiology of AMD and drug response variability	356
20.4. Current therapeutic landscape in AMD.	358
20.5. Personalized medicine in ophthalmology	359
20.6. AI approaches for drug response prediction in AMD	360
20.6.1. Imaging-based prediction models	361
20.6.2. Genomic and molecular data integration	361
20.6.3. Multimodal fusion models.	361
20.6.4. Time-series and longitudinal modeling	362
20.6.5. Explainability and clinical interpretability	362
20.7. Challenges in data, bias and model generalizability	364
20.7.1. Data availability and quality.	364
20.7.2. Algorithmic bias and equity concerns	364
20.7.3. Model generalizability and validation	364
20.8. The actual purpose of AI	365
20.9. Future directions	366
20.9.1. Multi-omics integration	366
20.9.2. Real-world data and continuous learning	366
20.9.3. Federated and privacy-preserving learning	366
20.9.4. Hybrid human–AI collaboration	367
20.9.5. Expansion beyond anti-VEGF therapies.	367
20.9.6. Toward a learning healthcare system	367
20.10. Conclusion.	367
20.11. References	368
List of Authors	371
Index	375